H E Bays
Bays H, Maki K, McKenney J, Snipes R, Meadowcroft A, Schroyer R, et al
. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin. 2010;26:907-15 pubmed publisher
..26 mmol/L and 5.64 mmol/L). NCT00903409. ..
Bays H, Braeckman R, Ballantyne C, Kastelein J, Otvos J, Stirtan W, et al
. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012;6:565-72 pubmed publisher
Bays H, Averna M, Majul C, Muller Wieland D, De Pellegrin A, Giezek H, et al
. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol. 2013;112:1885-95 pubmed publisher
Bays H, Goldberg R. The 'forgotten' bile acid sequestrants: is now a good time to remember?. Am J Ther. 2007;14:567-80 pubmed
Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009;25:671-81 pubmed
..Reduction of renal glucose reabsorption is a novel approach to DM treatment that potentially provides improvements in glucose lowering. Various SGLT2 inhibitors are currently in development in human trials. ..
Bays H, McKenney J, Maki K, Doyle R, Carter R, Stein E. Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc. 2010;85:122-8 pubmed publisher
..Prescription omega-3-acid ethyl esters plus atorvastatin produced significant improvements in non-HDL-C and other lipid parameters in patients with elevated non-HDL-C and triglyceride levels. ..
Bays H, Schwartz S, Littlejohn T, Kerzner B, Krauss R, Karpf D, et al
. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011;96:2889-97 pubmed publisher
..MBX-8025 also reduced liver enzyme levels. MBX-8025, a novel PPAR-? agonist, favorably affected multiple metabolic parameters with and without atorvastatin. A more complete understanding of MBX-8025 requires a larger future study. ..
Bays H. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther. 2011;9:265-77 pubmed publisher
..This article profiles lorcaserin as an illustrative example of general drug development regulatory processes, and specifically details the unique challenge of weight-loss drug development. ..
Bays H. The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Drugs R D. 2006;7:289-302 pubmed